On page 3331 of the original article, the word, ‘‘/LYXUMIA’’ has been removed from the section RATIONALE FOR COMBINATION THERAPY COMPRISING GLP-1 RAs AND BASAL INSULIN and the associated reference, numbered 100, has been corrected to: Xultophy® (insulin degludec/liraglutide) [summary of product characteristics]. Bagsvaerd, Denmark: Novo Nordisk A/S https://www.ema.europa.eu/ en/documents/product-information/xultophyepar- product-information_en.pdf. Accessed November 2019.
Handelsman, Y., Muskiet, M. H. A., & Meneilly, G. S. (2019). Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine (Advances in Therapy, (2019), 36, 12, (3321-3339), 10.1007/s12325-019-01126-x). Advances in therapy. https://doi.org/10.1007/s12325-019-01185-0